Text Size

Contrast Sensitivity in Glaucoma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2009 by University of Erlangen-Nürnberg Medical School.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Erlangen-Nürnberg Medical School
ClinicalTrials.gov Identifier:
NCT00947869
First received: July 27, 2009
Last updated: NA
Last verified: July 2009
History: No changes posted
  Purpose

The primary aim of the Erlangen´s Glaucoma Contrast Sensitivity-Study (EGCS-Study) is the evaluation of the diagnostic and prognostic validity of a diagnostic procedure, measuring contrast sensitivity. No therapeutic studies are performed.


Condition
Primary Open Angle Glaucoma
Secondary Open Angle Glaucoma Due to PEX

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Glaucoma Including Pseudoexfoliation Syndrome (SFB 539)

Resource links provided by NLM:

MedlinePlus related topics: Glaucoma
U.S. FDA Resources

Further study details as provided by University of Erlangen-Nürnberg Medical School:

Estimated Enrollment: 30
Study Start Date: April 2009
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

primary care clinic

Criteria
  • Patients: Primary open angle glaucoma, secondary open angle glaucoma due to PEX
  • Healthy volunteers (for reliability analysis)

Inclusion Criteria:

  • Age > 18
  • Best corrected visual acuity 0.8 or better
  • European

Exclusion Criteria:

  • eye diseases: Infantile glaucoma, angle glaucoma, secondary open angle glaucoma, wich are not due to PEX, diseases involving retina, condition after ophthalmological operations or trauma, cataract, diseases concerning the refractive system, age-related macular degeneration, diabetic retinopathy, optic neuropathy (MS, neuritis), amblyopia
  • Any neurological diseases
  • Systemic diseases with potentially ocular involvement (e.g., diabetes mellitus)
  • Systemic drugs with potentially ocular involvement
  • ocular drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00947869

Contacts
Contact: Anselm G Juenemann, Prof. anselm.juenemann@uk-erlangen.de

Locations
Germany
University Eye Hospital Recruiting
Erlangen, Bavaria, Germany, 91054
Contact: Hohberger     **49-9131-8534521        
Sponsors and Collaborators
University of Erlangen-Nürnberg
Investigators
Study Chair: Anselm G Juenemann, Prof. University Erlangen-Nuremberg
  More Information

No publications provided

Responsible Party: University Eye Hospital Erlangen, University of Erlangen-Nürnberg
ClinicalTrials.gov Identifier: NCT00947869     History of Changes
Other Study ID Numbers: DFG-SFB539-H
Study First Received: July 27, 2009
Last Updated: July 27, 2009
Health Authority: Germany: Ethics Commission

Additional relevant MeSH terms:
Glaucoma
Glaucoma, Open-Angle
Exfoliation Syndrome
Ocular Hypertension
 Eye Diseases
Iris Diseases
Uveal Diseases

ClinicalTrials.gov processed this record on May 23, 2013